๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for CML (Chronic Myelogenous Leukemia)

Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial NCT06355583Phase 28 sites๐Ÿ“ Birmingham๐Ÿ“ Leeds๐Ÿ“ London Imperial College London ยท Tests: EBX-102, Placebo Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia NCT03263572Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Blinatumomab, Cytarabine, Methotrexate, Ponatinib Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site๐Ÿ“ Minneapolis Masonic Cancer Center, University of Minnesota ยท Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen NCT01890486n/a1 site๐Ÿ“ Winston-Salem Wake Forest University Health Sciences Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies NCT06904066Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: aldesleukin, cyclophosphamide, fludarabine phosphate, Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500 Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML NCT06757855Phase 1, Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: Olverembatinib, Venetoclax, Azacitidine A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany NCT07549516n/a69 sites๐Ÿ“ Baden-Baden๐Ÿ“ Heidenheim๐Ÿ“ Schwรคbisch Hall Novartis Pharmaceuticals A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) NCT01351545n/a142 sites๐Ÿ“ Birmingham๐Ÿ“ Gilbert๐Ÿ“ Phoenix Center for International Blood and Marrow Transplant Researโ€ฆ ยท Tests: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors NCT03934372Phase 1, Phase 223 sites๐Ÿ“ Ghent๐Ÿ“ Paris๐Ÿ“ Paris Incyte Biosciences International Sร rl ยท Tests: Ponatinib HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant NCT03326921Phase 11 site๐Ÿ“ Seattle Fred Hutchinson Cancer Center ยท Tests: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT NCT07302776Phase 11 site๐Ÿ“ Palo Alto Stanford University ยท Tests: Tacrolimus, Early Tacrolimus Taper Strategy Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy NCT03630991Phase 11 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Edetate Calcium Disodium, Multivitamin, Succimer A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy NCT07091019n/a17 sites๐Ÿ“ Birmingham๐Ÿ“ Stockton๐Ÿ“ Torrance Novartis Pharmaceuticals ยท Tests: TKIs Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia NCT06082804NA1 site๐Ÿ“ Avignon Centre Hospitalier Henri Duffaut - Avignon ยท Tests: APN and medical management, Medical management, Quality of life assessment, Treatment compliance assessment A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation NCT06859424Phase 213 sites๐Ÿ“ Birmingham๐Ÿ“ Duarte๐Ÿ“ Palo Alto Center for International Blood and Marrow Transplant Researโ€ฆ ยท Tests: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E Study of Olverembatinib (HQP1351) in Patients With CML-CP NCT06423911Phase 3163 sites๐Ÿ“ Birmingham๐Ÿ“ Anchorage๐Ÿ“ Goodyear Ascentage Pharma Group Inc. ยท Tests: olverembatinib, Bosutinib Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia NCT02115295Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Cladribine, Cytarabine, Gilteritinib, Idarubicin, Laboratory Biomarker Analysis Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor NCT07238712Phase 21 site๐Ÿ“ Saint Petersburg St. Petersburg State Pavlov Medical University ยท Tests: Ruxolitinib, Abatacept (Orencia) Asciminib RMP Study NCT05943522n/a17 sites๐Ÿ“ Wลnju๐Ÿ“ Anyang-si๐Ÿ“ Bucheon-si Novartis Pharmaceuticals ยท Tests: Asciminib TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients NCT06453902Phase 21 site๐Ÿ“ Beijing Shenzhen TargetRx Co., Ltd. ยท Tests: TGRX-678 ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML NCT03595917Phase 14 sites๐Ÿ“ Chicago๐Ÿ“ Boston๐Ÿ“ Boston Marlise Luskin, MD ยท Tests: ABL001, Dasatinib, Prednisone, Blinatumomab Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling NCT05857969Phase 11 site๐Ÿ“ Miami Florida International University ยท Tests: Functional Precision Medicine MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing NCT05794880NA1 site๐Ÿ“ Milwaukee Medical College of Wisconsin ยท Tests: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi) Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia NCT05130138NA1 site๐Ÿ“ Saint-Etienne Centre Hospitalier Universitaire de Saint Etienne ยท Tests: Pharmaceutical intervention Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. NCT06514534Phase 26 sites๐Ÿ“ Bordeaux๐Ÿ“ Lille๐Ÿ“ Lyon Novartis Pharmaceuticals ยท Tests: ABL001/Asciminib Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy NCT06130787NA17 sites๐Ÿ“ Annecy๐Ÿ“ Bordeaux๐Ÿ“ Caen University Hospital, Clermont-Ferrand ยท Tests: Blood and bone marrow sample Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning NCT03852407Phase 210 sites๐Ÿ“ Antwerp๐Ÿ“ Bruges๐Ÿ“ Brussels University of Liege ยท Tests: Thymoglobulin, Melphalan, Fludarabine, Cyclophosphamid ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants NCT06787144Phase 14 sites๐Ÿ“ Akita๐Ÿ“ Sapporo๐Ÿ“ Suita-shi Enliven Therapeutics ยท Tests: ELVN-001 Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission NCT05439889n/a1 site๐Ÿ“ Taipei National Taiwan University Hospital
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy